Skip to Content

Posts tagged with "The Dark Side"

  • Cardiovascular Disease

    A Clinical Trial Torpedoed By Fraud and Incompetence

    Via @AndyBiotech on Twitter, here’s a story on some very troubling developments in offshore clinical trials. That Cardiobrief article is referring to this letter in NEJM, and the subject is the NIH’s trial of spironolactone in heart failure patients. The TOPCAT trial enrolled 3445 participants  in 6 countries (1151 in the US, 326 i… Read More
  • Business and Markets

    Lose Money Now! Ask Me How!

    Some readers will remember some odd moves in small biotechs like Galena Biosciences, Cytrx, and Lion Biotechnologies, among others. It can be hard to keep track, because there’s a lot of odd behavior down in those companies (here’s another recent example with Cyclacel). Here’s a welcome update to the earlier stories, courtesy of t… Read More
  • The Dark Side

    The Predatory Beat Goes On

    I’m not the least bit surprised by this effort. The predatory junk journals will do what ever they can think of to bring in customers and cash, with no restrictions and no shame: . . .we created a profile of a fictitious scientist named Anna O. Szust and applied on her behalf to the editorial… Read More
  • Business and Markets

    Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old generic steroid to the US market. They did no new registrational studies in the clinic, in case you’re wondering. There was a drug-drug interaction study, ADME work, that sort of thing… Read More
  • Drug Prices

    The Case of Marathon Pharmaceuticals

    So since drug pricing and FDA regulations are so much in the news, it would seem like the perfect time for a small company to game the system for big profits, right? That’s apparently what Marathon Pharmaceuticals believes. They just got approval for deflazacort, a steroid, as a treatment for Duchenne Muscular Dystrophy. Duchenne is… Read More
  • Business and Markets

    Not Quite What Friends Are For

    Folks who do industrial drug research know that they’re around proprietary information, and they generally know to keep quiet about it. That can be a bit of an odd feeling at first – I can remember getting together with some friends from school not long after I’d taken my first pharma job (they had also… Read More
  • The Dark Side

    The Predatory Publishers List Goes Dark

    I’ve been meaning to write about the sudden demise of Beall’s List of Predatory Publishers. I’ve referred to it several times over the years in posts about the lower (much lower) end of the scientific publishing world, and used it many times as a resource. To recap, while there are many reputable open-access publishers in… Read More
  • Cancer

    Be Sure The Funds Are Deposited

    I’ve written before here about the many people who are convinced that most (or all) diseases have to do with the body’s pH – most often, you hear that your body has to be alkaline, and that cancer and other diseases are associated with acidity. To save time, I will stipulate that this is bullshit. Read More
  • The Dark Side

    A Field Guide to Authorship Fraud

    Here’s a good overview at Nautilus of the various sorts of authorship fraud that takes place with scientific publications. The authors, Adam Marcus of Gastroenterology & Endoscopy News and Ivan Oransky of Retraction Watch, are focusing especially on the schemes that invent authors, co-authors, reviewers and so on, with many useful exampl… Read More
  • The Dark Side

    Unbowed at Theranos

    If you haven’t read this story on the person who appears to be the main Theranos whistleblower, do so immediately. Tyler Shultz is the grandson of George Shultz, who was one of the big names on the company’s board, and he started out enthusiastically. But as time went on, he realized that things were not… Read More
123...